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HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V/I 
during virological failure of first line antiretroviral therapy and is associated with 
compensatory mutation L74I. 
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summary:  
Lamivudine is a cornerstone antiretroviral whose efficacy has been ascribed to high 
fitness cost of the lamivudine resistance mutation M184V. However, here we 
demonstrate elevated viral loads in the context of M184V, likely attributable to 
compensatory mutations such as L74I. 
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Abstract  
Background: M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) 
resistance, and increased tenofovir (TDF) susceptibility. Nonetheless, 3TC and FTC 
(collectively referred to as XTC) appear to retain modest activity against HIV-1 with 
these mutations possibly as a result of reduced replication capacity. Here we 
determined how M184V/I impacts virus load (VL) in patients failing therapy on a 
TDF/XTC plus nonnucleoside RT inhibitor (NNRTI)-containing regimen. 
Methods: We compared VL in absence and presence M184V/I across studies using 
random effects meta-analysis. The effect of mutations on virus RT activity and 
infectiousness was analysed in vitro.  
Results: M184I/V was present in 817 (56.5%) of 1445 individuals with VF. VL was 
similar in individuals with or without M184I/V (difference in log10VL 0.18, 95% CI 
0.05-0.31). CD4 count was lower both at initiation of ART and at VF in participants 
who went on to develop M184V/I. L74I was present in 10.2% of persons with 
M184V/I but absent in persons without M184V/I (p<0.0001). In vitro, L74I 
compensated for defective replication of M184V mutated virus. 
Conclusion: Virus loads were similar in persons with and without M184V/I during VF 
on a TDF/XTC/NNRTI-containing regimen. We therefore do not find evidence for a 
benefit of XTC in the context of first line failure on this combination.  
 
Key words: antiretroviral; drug resistance; HIV; Lamivudine; fitness cost; 
compensatory mutation 
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Introduction 
The global scale up of antiretroviral therapy (ART) using a public health approach 
with limited viral load monitoring has been accompanied by high prevalence of drug 
resistance to NNRTI containing regimens amongst individuals with virological failure 
in LMIC, 1-3 4-6.  
 
The cytosine analogues lamivudine (3TC) and emtricitabine (FTC), collectively 
referred to as XTC, are components of first and second line regimens recommended 
by WHO. However, high level XTC resistance can be conferred and selected by 
single amino acid changes at position 184 of RT in the highly conserved (Y183, 
M184, D185, D186) amino acid domain that includes the active (catalytic) site of the 
p66 polymerase subunit of RT7. M184V/I are the most commonly occurring drug-
resistance mutations in persons with acquired resistance to first-generation NNRTI 
containing regimens1-3 4-6.  
 
Several lines of evidence suggest that in addition to causing high-level reductions in 
XTC susceptibility in vitro and modestly increased TDF susceptibility, viruses with 
these mutations retain some in vivo susceptibility to XTC possibly because of their 
reduced replication capacity8-10. For example early studies showed that in patients 
receiving 3TC monotherapy, or dual therapy with AZT/3TC, VL did not return to 
baseline despite the development of M184V9, 11-14. In addition, discontinuation of 
lamivudine during combination ART was associated with a modest increase in VL15-
17. By contrast the COLATE study, a randomised controlled trial conducted in Europe 
in the early 2000s, showed there was no effect of removal of lamivudine from a 
failing regimen where the endpoint was viral suppression to <200 copies/ml or viral 
load change of 1.4log1018.  
To understand the relationship between M184I/V and viral load in the era of tenofovir 
based cART where TAMs were not present, and also in the context of limited or no 
access to viral load monitoring, we therefore studied individuals failing the WHO 
recommended regimen first line regimen TDF/Xtc/NNRTI across a range of settings. 
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Methods 
The study population has previously been described and is presented in 
Supplementary Table 120-41. Patients treated with tenofovir disoproxil fumarate (TDF) 
plus 3TC/FTC and NVP/EFV were included where there was documented virologic 
failure (VF) and RT sequence data from codons 40-240 were available. VF was 
locally determined, and for low-middle income countries (LMIC) the threshold was 
1000 copies/ml. HIV-1 RT sequences were determined by standard Sanger 
sequencing at individual study sites.  
 
Mutations were defined as amino acid differences at positions 1 to 240 between 
each sequence and the consensus subtype B amino acid referen e sequence. As 
some individuals may have been exposed to thymidine analogues prior to TDF-
containing regimens5, we excluded individuals with sequences containing thymidine 
analogue mutations (TAMs) – M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E. 
 
Each sequence was subtyped as previously described and sequence quality control 
measures were taken to identify sequences with APOBEC G-to-A hypermutation20. 
Duplicate sequences were removed. All patients reported that they were ARV naïve 
at baseline. The primary outcome was viral load at VF, hence patients without this 
outcome were excluded. 
 
Statistical analysis 
We graphically compared the distribution of log10 viral loads according to presence 
of M184I/V mutation both within and across studies. To quantify the impact of 
M184I/V on viral load, we calculated mean log10 viral load in each study according 
to M184I/V. Differences were pooled across studies using random effects meta-
analysis. Estimates of the standard error in each study were calculated by dividing 
the pooled estimate of the standard deviation by the square root of the number of 
patients with/without M184I/V in any given study. We repeated this process in 
subgroups of patients defined by several baseline characteristics: presence of K65R 
mutation, presence of major NNRTI mutations, choice of NRTI, choice of NNRTI, 
categories of baseline CD4 count (< and > 200 cells/mm3) and categories of baseline 
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viral load (< and > 100,000 copies per mL).  Analyses of CD4 count and treatment 
failure used the same methods. To assess whether M184I/V was associated with 
viral load at failure independently of other mutations, we performed a separate 
analysis in which we used a mixed linear regression model adjusting for study as a 
random effect and other mutations associated with increased viral load (which were 
identified by forward stepwise variable selection). Next, we used Fisher’s exact test 
to identify mutations associated with M184I/V.  We used two-sided p-values and 
Stata version 15.1 for all statistical analyses.  
In vitro analyses 
A patient derived pol sequence was identified with mutations of interest and the gag-
PR-RT-IN region amplified by PCR with flanking restriction sites inserted into 
primers. Following cloning into an expression plasmid, site directed mutagenesis 
was performed to revert (i) isoleucine back to leucine at RT amino acid 74, (ii) valine 
back to methionine at RT amino acid 184, or both. Plasmids expressing gag-pol 
were co-transfected into 293T cells along with a VSV-G envelope expressing 
plasmid and a vector encoding luciferase expressed from an LTR promoter as 
previously described42. Supernatant containing virus was harvested 2 days later and 
used to infect fresh 293T cells. Luminescence as a read out of infection was read by 
luminometry 2 days later. Viral p24 abundance in supernatants was estimated using 
western blot using a p24 antibody as previously described43. 
Results 
Amongst 2873 participants included in the initial group, 1445 from 32 study groups 
across 15 countries had an available failure viral load measurement of which 
M184I/V was present in 817 (56.5%) (Table 1 and supplementary Table 1). 
Participants were from sub-Saharan Africa (55.4%), Asia (19.2%), Europe (16.2%) 
and North America (9.3%). All participants were on TDF, most of them also treated 
with EFV (75.2%) and 3TC (64.5%), and participants harboring M184I/V mutated 
virus were significantly more likely to have high level tenofovir and NNRTI resistance 
(Table 1B). Participants harboring M184I/V were also more likely to have multiple 
NNRTI mutations. 
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In a crude comparison of viral load at failure, patients with M184I/V present had a 
higher median log 10 viral load (4.7, interquartile range (IQR): 3.4-5) than patients 
without M184I/V (median 4.3, IQR 4.1-5.3). When restricting analyses to 
comparisons of patients within the same study, the estimated difference in viral load 
was non-significant in the vast majority of studies (Figure 1). When within-study 
differences were pooled across studies, there was a marginally higher viral load in 
patients with M184I/V present compared to absent (pooled difference in log10 viral 
load 0.18, 95% CI 0.05-0.31) (Figure 2). Following statistical adjustment for other 
mutations independently associated with increased viral load, M184I/V was no 
longer significantly associated with viral load at failure. However, the estimated 
difference and 95% confidence interval (0.09, 95% CI -0.01 to 0.20) excluded any 
meaningful decrease in failure viral load associated with M184I/V. There was no 
evidence that relationship between M184I/V and failure viral load was modified by 
choice of NRTI, choice of NNRTI, or drug resistance to NNRTI or tenofovir (Figure 
2).   
We next explored the relationship between detection of M184I/V failure and CD4 
count, noting that the duration of VF was likely longer in LMIC regions. Mean 
baseline CD4 was significantly lower amongst patients who went on to develop 
M184I/V by treatment failure compared to those who did not (88 vs 180, p<0.0001). 
Similarly, at VF, presence of M184V/I was associated with lower CD4 count, though 
the difference was greater (Figure 3). Between baseline and treatment failure, CD4 
count increased to a similar extent in patients with and without M184I/V (median 
increase: 79 vs 48 cells/mm3, p=0.55). 
We next examined NRTI mutations associated with M184V/I that might play a 
compensatory role for M184I/V. We looked for associations in the dataset between 
M184V/I and RT amino acid positions known to be associated with drug exposure. 
Figure 4 shows mutations with strong evidence of an association with M184I/V. 
Many of these mutations have previously been associated with drug resistance to 
tenofovir, either directly (K65R, K70E) or as compensatory mutations for K65R 
(A62V, S68N, F155Y). The following NNRTI mutations were also associated (A98G, 
L100I, K103R, V108I, Y181C, Y188L, G190A, P225H, L228R, M230L).  
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Of note, L74I was the only mutation to be exclusively associated with M184V/I, 
occurring in 83 (10.2%) of patients with M184I/V, and in none of the 628 patients in 
which M184I/V was absent (p for association <0.0001). L74I was observed in 11.7% 
of subtype C infected participants with M184I/V at VF, and in 14.4% of CRF01_AE 
participants with M184I/V at VF (Supplementary Table 2).  
Given a previous report that L74I can restore replication to a virus with the K65R 
mutation without conferring drug resistance44, we next sought to test the hypothesis 
that L74I could restore replication ‘fitness’ to a M184V mutant virus, explaining the 
higher than expected viral loads. Molecular characterisation of virus with the 
mutations M184V and L74I was undertaken. The viral isolate tested also had the 
NNRTI resistance mutations A98G, K103N and P225H. Site directed mutagenesis 
was performed to revert isoleucine back to leucine at 74 and Valine to Methionine at 
184 (Figure 5A). We did not however assess the impact of M184I. We measured (i) 
infectivity of these viruses and (ii) reverse transcriptase efficiency in a single round 
replication assay (Figure 5). We found that removing the L74I mutation significantly 
decreased the efficiency of reverse transcription (Figure 5B, compare left bar with 
middle bar) whilst virus abundance was not affected as determined by western blot 
of viral p24 abundance in supernatants (Figure 5B bottom panel). Infectivity was also 
significantly decreased by reversion of the compensatory mutation (Figure 5C, 
compare left bar with middle bar). Mutation of M184V back to M, leaving a virus with 
only L74I, had no impact on reverse transcriptase efficiency and a minor effect on 
infectivity (Figure 5B, C compare left and right bars). 
 
Discussion 
Despite having a low genetic barrier to drug resistance, lamivudine has retained 
importance and a central role in both first and second line ART 45. A complete 
understanding of lamivudine efficacy is therefore important, particularly given reports 
suggesting that lamivudine use confers viral load benefit despite high level 
resistance to the drug in the form of the M184V/I. 
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Our primary finding that viral load was similar in participants with and without 
M184V/I at the time of VF was robust across baseline CD4 count, baseline viral load, 
gender, and different NNRTI and NRTI drugs in the first line treatment regimen. We 
observed lower baseline and VF CD4 counts in individuals with M184V/I, though rate 
of change of CD4 did not differ based on M184V/I status. Lower baseline CD4 count 
is known to be associated with higher VF rates and a higher probability of drug 
resistance at VF6, 46. A possible explanation for this finding is that the antiviral effect 
of a competent immune system is important in limiting replication and emergence of 
resistance in tissue compartments where ARV drug penetration is suboptimal. A 
lower CD4 count at VF in the group with M184V/I further argues against this 
mutation being ‘protective’ or ‘benign’. These data are also consistent with reports of 
the pathogenic potential of M184V containing viruses in both humans47 and animal 
models48. 
 
We identified L74I as being specifically enriched in i dividuals with M184V and not 
present at all in those without M184V/I. We observed significant prevalence of L74I 
in subtypes C and CRF01_AE, though limited numbers of participants across 
subtypes limited a full understanding of subtype distribution. In vitro experiments 
demonstrated that L74I restores replication efficiency to a virus with the M184V 
mutation over a single round of infection, and that enhancement was due to 
efficiency of HIV reverse transcription in viral particles.  
 
The emergence of L74I exclusively in patients with M184V/I suggests an in vivo 
selection advantage of L74I + M184V replication over M184V alone at least in some 
individuals. L74I was first reported as a mutation associated with exposure to 
abacavir or less commonly tenofovir49, 50, and it appeared more common in patients 
with thymidine analogue mutations50. Correlation with M184V/I has not been made to 
date and in vitro experiments not performed with L74I + M184V/I containing viruses.  
 
As L74I was observed only in around 10% of those with M184V/I, we postulate that 
alternative mutations, less strongly linked to M184V/I or perhaps outside the region 
of the pol gene sequenced in this study, could have similar effects as L74I in 
participants with M184V/I. Data from our study support the transmission potential of 
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M184V/I containing viruses in the context of prolonged virological failure and 
accumulated co-evolved mutations in RT that occurs under ‘real world’ conditions.  
 
Limitations of this study include its retrospective cross-sectional design, absence of 
drug levels or adherence data and unknown duration of VF for participants. Our 
study was not designed to provide a mechanistic understanding of the relationship 
between M184 and fitness, rather to understand the pathogenic potential of M184V 
containing viruses in treated ‘real world’ patients. Finally. there was heterogeneity 
between population groups, and to account for this, analyses were conducted within 
study. It should also be noted that stratification by tenofovir or NNRTI resistance 
resulted in small numbers for sub analyses.  
 
In summary, we show that lamivudine resistant and susceptible viruses show similar 
viral loads in patients failing NNRTI based ART containing lamivudine, tenofovir and 
NNRTI, likely in part due to viral evolution of compensatory changes that maintain 
replication efficiency of M184V/I containing viruses. These data reinforce the 
importance of effective viral load monitoring to limit HIV drug resistance and disease 
progression in the face of suboptimal drug pressure, particularly in low resource 
settings. Finally, given that we did not find benefit of lamivudine in failing first line 
patients, a prospective clinical trial could to determine whether there is benefit for 
including XTC in second-line regimens for the treatment of persons whose viruses 
develop M184I/V following VF on a first-line treatment regimen. 
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Table 1: Baseline characteristics of participants by geographic region 
Table 2: Summary of drug resistance characteristics of participants at virological 
failure with tenofovir + cytosine analogue + NNRTI by geographical region 
Figure 1: Difference in viral load by mutations at RT position 184 in study groups 
with 95% confidence interval using random effects meta-analysis. Boxes represent 
mean with 95% CI. Estimates to the right indicate higher viral load in the presence of 
M184V/I, and estimates to the left lower viral load in presence of M184V/I. 
Figure 2: Association of M184V/I mutation with log10 viral load across subgroups. 
Diamonds represent mean with 95% CI. Estimates to the right indicate higher viral 
load in the presence of M184V/I. 
Figure 3: Differences in CD4 count during virological failure within studies by 
presence and absence of M184V/I. Boxes represent mean with 95% CI. Estimates to 
the left of centre line indicate lower CD4 count in participants with M184V/I.  
Figure 4: HIV reverse transcriptase inhibitor resistance associated mutations 
enriched in virologically failing participants (n=1445) with M184V/I. Mutations are 
shown that occurred in at least 10% of individuals with M184V/ at a significance level 
of <0.001.  
 
Figure 5. In vitro replication measurement of lamivudine resistant subtype C clinical 
isolate containing M184V and L74I and revertant mutations. A. Amino acid multiple 
sequence alignment of clinical isolate and revertant mutants generated by site 
directed mutagenesis. Numbering is relative to strain HXB2. B. In vitro reverse 
transcription efficiency contained in pelleted single round virus from cells producing 
clinical HIV isolate RT sequence and mutants. Bottom panel shows western blot of 
corresponding virus associated p24 in supernatants from cells. C. Single round 
infection of target HEK 293T cells by equal quantities of luciferase expressing VSV-
G pseudotyped HIV viruses from B. Data in B and C were performed in replicate and 
means are presented with error bars corresponding to standard deviation. RLU: 
relative light units. 
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Region M184 I/V Patients EFV 3TC  Baseline CD4 count  Baseline log10 viral load 
      N 
with 
data 
  N 
with 
data 
 
Overall No 628 523 (83.3%) 350 (55.7%)  351 180.0 (82.0 to 288.0)  253 5.0 (4.5 to 5.5) 
 Yes 817 564 (69.0%) 582 (71.2%)  385 88.0 (36.0 to 165.0)  187 5.2 (4.7 to 5.7) 
Sub-saharan 
Africa 
No 257 198 (77.0%) 204 (79.4%)  142 148.0 (69.0 to 264.0)  43 5.3 (4.5 to 5.7) 
 Yes 543 356 (65.6%) 430 (79.2%)  270 77.0 (35.0 to 138.0)  71 5.3 (4.7 to 5.7) 
Asia No 136 112 (82.4%) 110 (80.9%)  0 -  0 - 
 Yes 141 121 (85.8%) 122 (86.5%)  4 69.5 (33.5 to 159.0)  5 4.7 (4.6 to 5.9) 
Europe No 146 127 (87.0%) 25 (17.1%)  138 199.5 (84.0 to 304.0)  136 5.0 (4.6 to 5.5) 
 Yes 88 53 (60.2%) 23 (26.1%)  77 157.0 (62.0 to 232.0)  76 5.1 (4.8 to 5.7) 
North America No 89 86 (96.6%) 11 (12.4%)  71 204.0 (98.0 to 351.0)  77 4.7 (4.3 to 5.3) 
 Yes 45 34 (75.6%) 7 (15.6%)  34 67.5 (27.0 to 156.0)  35 5.2 (4.8 to 5.6) 
 
Table 1 
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Region M184 
I/V  
TDF 
resistance, n 
(%) 
At least one 
major NNRTI 
mutation, n 
(%) 
Number of 
NNRTI 
mutations, 
mean (SD) 
Failure log10 viral 
load 
 Failure CD4 count, 
median (IQR)  
      N 
with 
data 
Median (IQR) 
Overall No 137 (21.8%) 380 (60.5%) 1.2 (1.3) 4.3 (3.4 to 5.0) 237 263.0 (121.0 to 382.0) 
 Yes 539 (66.0%) 792 (96.9%) 2.9 (1.3) 4.7 (4.1 to 5.3) 211 104.0 (29.0 to 236.0) 
Sub-saharan 
Africa 
No 80 (31.1%) 175 (68.1%) 1.5 (1.4) 
4.7 (3.9 to 5.2) 
29 262.0 (180.0 to 360.0) 
 Yes 400 (73.7%) 531 (97.8%) 2.9 (1.3) 4.8 (4.1 to 5.3) 52 137.0 (20.0 to 219.0) 
Asia No 30 (22.1%) 91 (66.9%) 1.3 (1.4) 4.8 (4.1 to 5.3) 119 188.0 (71.0 to 355.0) 
 Yes 82 (58.2%) 130 (92.2%) 2.9 (1.5) 4.9 (4.2 to 5.3) 118 87.5 (29.0 to 229.0) 
Europe No 20 (13.7%) 65 (44.5%) 0.7 (1.0) 3.4 (2.7 to 4.6) 32 323.0 (238.0 to 387.0) 
 Yes 38 (43.2%) 86 (97.7%) 2.6 (1.4) 4.2 (3.8 to 4.8) 12 242.5 (122.0 to 345.0) 
North America No 7 (7.9%) 49 (55.1%) 0.8 (0.9) 3.4 (2.4 to 4.3) 57 312.0 (198.0 to 476.0) 
 Yes 19 (42.2%) 45 (100.0%) 2.8 (1.4) 4.2 (3.7 to 4.7) 29 173.0 (42.0 to 329.0) 
 
Table 2 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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